PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Discussing a T2D Medication That Could Reduce Insulin Needs in T1D
MP3•Episode home
Manage episode 386156480 series 1147378
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: David Selzer, MD
New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.
…
continue reading
Guest: David Selzer, MD
New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.
211 episodes
MP3•Episode home
Manage episode 386156480 series 1147378
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: David Selzer, MD
New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.
…
continue reading
Guest: David Selzer, MD
New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.
211 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.